Search

Your search keyword '"Erhan Berrak"' showing total 2 results
Start Over Author "Erhan Berrak" Journal leukemia research reports
2 results on '"Erhan Berrak"'

1. Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia

Author

Jacques Delaunay, Grzegorz Mazur, Mark Minden, Agnieszka Wierzbowska, Mark M. Jones, Erhan Berrak, and Hagop M. Kantarjian

Subjects
Decitabine, Acute myeloid leukemia, Prognosis, Leukemia, Adult, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: In a phase III trial, older patients with acute myeloid leukemia (N=485) received decitabine or treatment choice (supportive care or cytarabine). This post hoc analysis examined whether baseline renal and hepatic function and white blood cell (WBC) counts predicted response. Methods: Baseline WBCs and renal and liver function markers were tabulated for responders/nonresponders. Results: Nonresponders had higher mean baseline creatinine (P=0.005). Creatinine data showed no significant between-group differences by treatment within responder category. Conclusions: No relationship was found between baseline WBCs or hepatic function and response. Higher baseline creatinine in nonresponders may not be clinically relevant.

Published
2014
Full Text
View/download PDF

2. Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia

Author

Agnieszka Wierzbowska, Hagop M. Kantarjian, Grzegorz Mazur, Erhan Berrak, Jacques Delaunay, Mark M. Jones, and Mark D. Minden

Subjects
Adult, medicine.medical_specialty, ECOG PS, Eastern Cooperative Oncology Group Performance Status, BUN, blood urea nitrogen, Decitabine, AST, aspartate aminotransferase, Gastroenterology, lcsh:RC254-282, Article, CRi, complete response with incomplete blood count recovery, hemic and lymphatic diseases, Internal medicine, White blood cell, ALT, alanine aminotransferase, Post-hoc analysis, medicine, Blood urea nitrogen, AML, acute myeloid leukemia, Acute myeloid leukemia, Leukemia, SC, supportive care, business.industry, PR, partial remission, Myeloid leukemia, Hematology, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Prognosis, medicine.anatomical_structure, Oncology, Immunology, CR, complete response, Cytarabine, business, medicine.drug, French–American–British classification, FAB, French–American–British classification, WBC, white blood cell
Abstract

Background: In a phase III trial, older patients with acute myeloid leukemia (N=485) received decitabine or treatment choice (supportive care or cytarabine). This post hoc analysis examined whether baseline renal and hepatic function and white blood cell (WBC) counts predicted response. Methods: Baseline WBCs and renal and liver function markers were tabulated for responders/nonresponders. Results: Nonresponders had higher mean baseline creatinine (P=0.005). Creatinine data showed no significant between-group differences by treatment within responder category. Conclusions: No relationship was found between baseline WBCs or hepatic function and response. Higher baseline creatinine in nonresponders may not be clinically relevant.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results